Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 210 pages | ID: G84DD58CFFFEN
Precision Business Insights (PBI)

Abstracts

Global Uveitis Treatment Market

Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn’s disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fuelling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.

Uveitis treatment market segmented based on drug class, disease type, by cause and distribution channel

Based on drug class, uveitis treatment market is segmented into

• Corticosteroids
• Immunosuppressant
• Monoclonal antibodies
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Based on disease type, uveitis treatment market is segmented into

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Based on cause, uveitis treatment market is segmented into

• Infectious Uveitis
• Non-Infectious Uveitis

Based on distribution channel, uveitis treatment market is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Others

Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period.

Geographically uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.

Some of the players in uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few.

In June 2016, U.S. Food and Drug Administration approved AbbVie’s HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL UVEITIS TREATMENT MARKET INTRODUCTION

2.1. Global Uveitis Treatment Market – Taxonomy
2.2. Global Uveitis Treatment Market –Definitions
  2.2.1. Drug Class Type
  2.2.2. Disease Type
  2.2.3. Cause
  2.2.4. Distribution Channel

3. GLOBAL UVEITIS TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Uveitis Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Uveitis Treatment Market – Product Innovations

4. GLOBAL UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Corticosteroids
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Immunosuppressant
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Monoclonal antibodies
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Antibiotics
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis
5.5. Antivirals
  5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.5.3. Market Opportunity Analysis
5.6. Antifungal
  5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.6.3. Market Opportunity Analysis
5.7. Analgesics
  5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.7.3. Market Opportunity Analysis

6. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Anterior Uveitis
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Posterior Uveitis
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Intermediate Uveitis
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis
6.4. Panuveitis
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.4.3. Market Opportunity Analysis

7. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY CAUSE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Infectious Uveitis
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Non-Infectious Uveitis
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis

8. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Others
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis

9. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  9.5.3. Market Opportunity Analysis
9.6. Global Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Disease Type, Cause, Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Corticosteroids
    10.1.1.2. Immunosuppressant
    10.1.1.3. Monoclonal antibodies
    10.1.1.4. Antibiotics
    10.1.1.5. Antivirals
    10.1.1.6. Antifungal
    10.1.1.7. Analgesics
  10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Anterior Uveitis
    10.1.2.2. Posterior Uveitis
    10.1.2.3. Intermediate Uveitis
    10.1.2.4. Panuveitis
  10.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Infectious Uveitis
    10.1.3.2. Non Infectious Uveitis
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospital Pharmacies
    10.1.4.2. Retail Pharmacies
    10.1.4.3. Others
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023
  10.1.7. North America Uveitis Treatment Market Dynamics – Trends

11. EUROPE UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Corticosteroids
    11.1.1.2. Immunosuppressant
    11.1.1.3. Monoclonal antibodies
    11.1.1.4. Antibiotics
    11.1.1.5. Antivirals
    11.1.1.6. Antifungal
    11.1.1.7. Analgesics
  11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Anterior Uveitis
    11.1.2.2. Posterior Uveitis
    11.1.2.3. Intermediate Uveitis
    11.1.2.4. Panuveitis
  11.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Infectious Uveitis
    11.1.3.2. Non Infectious Uveitis
  11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospital Pharmacies
    11.1.4.2. Retail Pharmacies
    11.1.4.3. Others
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023
  11.1.7. Europe Uveitis Treatment Market Dynamics – Trends

12. ASIA-PACIFIC UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Corticosteroids
    12.1.1.2. Immunosuppressant
    12.1.1.3. Monoclonal antibodies
    12.1.1.4. Antibiotics
    12.1.1.5. Antivirals
    12.1.1.6. Antifungal
    12.1.1.7. Analgesics
  12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Anterior Uveitis
    12.1.2.2. Posterior Uveitis
    12.1.2.3. Intermediate Uveitis
    12.1.2.4. Panuveitis
  12.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Infectious Uveitis
    12.1.3.2. Non Infectious Uveitis
  12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospital Pharmacies
    12.1.4.2. Retail Pharmacies
    12.1.4.3. Others
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023
  12.1.7. Europe Uveitis Treatment Market Dynamics – Trends

13. LATIN AMERICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Corticosteroids
    13.1.1.2. Immunosuppressant
    13.1.1.3. Monoclonal antibodies
    13.1.1.4. Antibiotics
    13.1.1.5. Antivirals
    13.1.1.6. Antifungal
    13.1.1.7. Analgesics
  13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Anterior Uveitis
    13.1.2.2. Posterior Uveitis
    13.1.2.3. Intermediate Uveitis
    13.1.2.4. Panuveitis
  13.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Infectious Uveitis
    13.1.3.2. Non Infectious Uveitis
  13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospital Pharmacies
    13.1.4.2. Retail Pharmacies
    13.1.4.3. Others
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023
  13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.1.1. Corticosteroids
    14.1.1.2. Immunosuppressant
    14.1.1.3. Monoclonal antibodies
    14.1.1.4. Antibiotics
    14.1.1.5. Antivirals
    14.1.1.6. Antifungal
    14.1.1.7. Analgesics
  14.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Anterior Uveitis
    14.1.2.2. Posterior Uveitis
    14.1.2.3. Intermediate Uveitis
    14.1.2.4. Panuveitis
  14.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Infectious Uveitis
    14.1.3.2. Non Infectious Uveitis
  14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Hospital Pharmacies
    14.1.4.2. Retail Pharmacies
    14.1.4.3. Others
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023
  14.1.7. MEA Uveitis Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. AbbVie Inc. (U.S.)
  15.2.2. Eyegate Pharmaceuticals Inc. (U.S.)
  15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada)
  15.2.4. Novartis AG (Switzerland)
  15.2.5. Alimera Sciences Inc. (U.S.)
  15.2.6. Santen Pharmaceutical Co. Ltd (Japan)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS